Clinical trials: Idarubicin
High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
This phase Ib/II trial studies the best dose and side effects of venetoclax and how well it works when given with combination chemotherapy in treating patients with newly diagnosed acute myeloid leukemia or acute myeloid leukemia…
- Conditions
- High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT03214562
- Testing
- Cytarabine, Filgrastim, Fludarabine
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- M.D. Anderson Cancer Center
Myeloid Leukemia
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
The goal of Phase 1b is to establish the safety of asciminib in combination with FLAG-Ida and venetoclax in patients with CML-MBP, CML-LBP, and Ph+ AML.
- Trial name
- NCT07604233
- Testing
- Fludarabine, Cytarabine, Idarubicin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
AML, Adult
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
This study is a multicenter, randomized, controlled phase III clinical trial aimed at comparing the efficacy of two induction chemotherapy regimens-VA (Venetoclax + Azacitidine) and D/IA (Daunorubicin/Idarubicin + Cytarabine)-in…
- Trial name
- NCT07132684
- Testing
- Daunorubicin/Idarubicin, Cytarabine, Azacitidine
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
This phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of acute myeloid…
- Trial name
- NCT07228273
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- OHSU Knight Cancer Institute
Acute Myeloid Leukemia
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
The purpose of this study is to evaluate whether HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cell (GPBMC) infusion with venetoclax-containing regimens (microtransplant, MST) could improve survival in adult…
- Trial name
- NCT07078591
- Testing
- Venetoclax, Azacitidine (AZA), Daunorubicin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing 302 Hospital
Acute Myeloid Leukemia
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
The current standard of care treatment for adult patients with acute myeloid leukemia (AML) consists of chemotherapy and, if indicated, donor stem cell transplantation.
- Trial name
- NCT07223814
- Testing
- Bleximenib, Cytarabine, Daunorubicin or Idarubicin
- Where
- 98 sites in United States, Australia and 11 more
- Volunteers
- 875 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating patients with newly diagnosed acute myeloid…
- Conditions
- Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, de Novo Myelodysplastic Syndrome
- Trial name
- NCT00801489
- Testing
- Cytarabine, Decitabine, Filgrastim-sndz
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myeloid, Acute
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of bleximenib in…
- Trial name
- NCT05453903
- Testing
- Bleximenib, Venetoclax (VEN), Azacitidine (AZA)
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 196 people
- Sponsor
- Janssen Research & Development, LLC
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
This phase I trial studies the best dose of total body irradiation when given with cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) or idarubicin, fludarabine, cytarabine and filgrastim (FLAG-Ida) chemotherapy…
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04375631
- Testing
- Cladribine, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
This is a phase 2 study to test the hypothesis that venetoclax in combination with standard chemotherapy will be tolerable and active in pediatric patients with newly diagnosed acute myeloid leukemia (AML).
- Trial name
- NCT05955261
- Testing
- Venetoclax, Azacitidine, Cytarabine
- Where
- 10 sites in United States
- Volunteers
- 70 people
- Sponsor
- St. Jude Children's Research Hospital
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
This screening and multi-sub-study Phase 1b/2/3 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of…
- Trial name
- NCT03013998
- Testing
- Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis
- Where
- 31 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Beat AML, LLC
Acute Myeloid Leukemia, Pediatric AML
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
This research study investigates the tolerability of substituting two cycles of chemotherapy into the standard pediatric acute myeloid leukemia (AML) chemotherapy treatment regimen for patients with newly diagnosed AML at…
- Trial name
- NCT07059975
- Testing
- Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Baylor College of Medicine
AML, AML With Mutated NPM1
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA…
- Conditions
- AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar
- Trial name
- NCT06001788
- Testing
- Ziftomenib, Fludarabine, Idarubicin
- Where
- 45 sites in United States, Italy and 1 more
- Volunteers
- 171 people
- Sponsor
- Kura Oncology, Inc.
Hepatocellular Carcinoma, Liver Cancer
TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients With Hepatocellular Carcinoma
Little is known about whether the types of chemotherapeutic agents affect the efficacy of transarterial chemoembolization in patients with hepatocellular carcinoma.
- Trial name
- IDADOX (NCT06114082)
- Testing
- IDA-TACE, DOX-TACE
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- Seoul National University Hospital
AML, Adult
MRD-positive AML Clinical Study
This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the…
- Trial name
- NCT07131059
- Testing
- Ivosidenib, Gilteritinib, Venetoclax
- Where
- China
- Volunteers
- 537 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
AML, Refractory
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options.
- Conditions
- AML, Refractory, Relapsed
- Trial name
- NCT06265545
- Testing
- Ivosidenib, Venetoclax, Gilteritinib
- Where
- China
- Volunteers
- 458 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
AML, RUNX1-RUNX1T1 Fusion Protein Expression
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
Leukemia is one of the common malignant tumors that threaten human health. Although the efficacy of AML treatment has improved significantly in recent years, it remains one of the major diseases threatening human health.
- Trial name
- NCT06744504
- Testing
- cytarabine, daunorubicin, idarubicin
- Where
- China
- Volunteers
- 284 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
This phase I trial finds the best dose of PVEK when given together with fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin, (FLAG-Ida) regimen and studies the effectiveness of this combination…
- Conditions
- Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT06034470
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
This phase II trial tests the safety, side effects, and how well combination chemotherapy with fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin (FLAG-Ida) followed immediately by…
- Conditions
- Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT07046078
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia (AML)
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60…
- Trial name
- BIG-1 (NCT02416388)
- Testing
- Idarubicin, Daunorubicin, HD Cytarabine
- Where
- 56 sites in France
- Volunteers
- 3,100 people
- Sponsor
- University Hospital, Angers